On November 12, 2026, the FDA approved Biocon’s Pebrilzo™ (pertuzumab-qcay) as a biosimilar of Genentech’s Perjeta® (pertuzumab). Pebrilzo™ is the second Perjeta® biosimilar approval, following Shanghai Henlius Biotech’s Poherdy® (pertuzumab-dpzb), approved as an interchangeable biosimilar in November 2025 (previously reported FDA Approves First Perjeta® Biosimilar: Shanghai Henlius Biotech / Organon’s Poherdy®).
In October 2026, Genentech and Biocon settled BPCIA litigation No. 2:26-cv-09585 (D.N.J.) allowing the launch of Pebrilzo™ in the third quarter of 2028, or earlier in certain undisclosed circumstances (previously reported Genentech and Biocon Settle Perjeta® BPCIA Litigation).
In January 2026, Genentech and Shanghai Henlius Biotech settled BPCIA litigation No. 2:25-cv-14648 (D.N.J.) related to Poherdy® (previously reported Genentech and Shanghai Henlius Biotech Settle Perjeta® Biosimilar BPCIA Litigation).
There are no other ongoing patent disputes related to Perjeta® biosimilars
Roche reported U.S. sales of approximately $1.62B USD (1.27B CHF) for Perjeta® in 2025.
For more information about these and other biosimilars, please visit BiologicsHQ.
_____________________________________________________
The author would like to thank April Breyer Menon for her contributions to this article.
